CHRNB4
- Known as:
- CHRNB4
- Catalog number:
- Y213938
- Product Quantity:
- 200ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- CHRNB4
Related genes to: CHRNB4
- Gene:
- CHRNB4 NIH gene
- Name:
- cholinergic receptor nicotinic beta 4 subunit
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 15q25.1
- Locus Type:
- gene with protein product
- Date approved:
- 1990-05-11
- Date modifiied:
- 2016-10-05
Related products to: CHRNB4
anti-CHRNB4 (Internal)Anti-CHRNB4, Goat Polyclonal to CHRNB4, Isotype , Host GoatBovine cholinergic receptor, nicotinic, beta 4 (CHRNB4) ELISA kit, Species Bovine, Sample Type serum, plasmaBovine Neuronal acetylcholine receptor subunit beta-4(CHRNB4) ELISA kitBovine Neuronal acetylcholine receptor subunit beta-4(CHRNB4) ELISA kit SpeciesBovineChicken cholinergic receptor, nicotinic, beta 4 (CHRNB4) ELISA kit, Species Chicken, Sample Type serum, plasmaChicken Neuronal acetylcholine receptor subunit beta-4(CHRNB4) ELISA kitChicken Neuronal acetylcholine receptor subunit beta-4(CHRNB4) ELISA kit SpeciesChickenCHRNB2 Gene cholinergic receptor, nicotinic, beta 2 (neuronal)CHRNB4 AntibodyCHRNB4 (Human) Recombinant Protein (Q01)CHRNB4 3&_39;UTR Lenti-reporter-Luc VectorCHRNB4 AntibodyCHRNB4 antibodyCHRNB4 Antibody (C-term) Related articles to: CHRNB4
- The clinical efficacy of the BCL-2 inhibitor venetoclax in acute myeloid leukemia (AML) is significantly undermined by the frequent emergence of drug resistance, which precipitates disease progression and poor patient outcomes. However, the molecular landscape of this resistance remains insufficiently understood. - Source: PubMed
Publication date: 2026/04/08
Koyama HiroakiSeo SachikoTse WilliamBian SichengLiu Shujun - A major challenge in treating AML with the BCL-2 inhibitor venetoclax is the frequent development of drug resistance, which diminishes therapeutic efficacy and leads to patient death. The fundamental mechanisms underlying this resistance are not fully understood. Here, we established venetoclax-resistant cell models of AML that propagate even when the levels of BCL-2, MCL-1, cleaved PARP, and cleaved caspase-9 are reduced, suggesting a BCL-2-independent resistance mechanism. Compared to sensitive cells, resistant Kasumi-1 (VENK) and MV4-11 (VENM) cells exhibit enhanced proliferation both and , forming larger and more numerous spheroids and colonies, and displaying higher tumorigenicity in mice. RNA sequencing and KEGG pathway analysis identified the neuroactive ligand-receptor interaction (NLRI) pathway as a key vulnerability in both resistant cell lines. While the NLRI pathway contains numerous altered genes, CHRNB4 is the only gene commonly shared and significantly downregulated in both VENK and VENM cells and tumors. Enforced expression of CHRNB4 in resistant cells with low basal expression impaired cell adhesion and colony formation. Clinically, CHRNB4 downregulation is associated with poor AML patient overall survival and predicts a diminished response to venetoclax treatment. This study identifies the NLRI pathway as a crucial vulnerability in venetoclax resistance and unveils CHRNB4 as a promising predictive biomarker for treatment response. These results suggest that targeting the NLRI pathway represents a novel strategy for developing next-generation therapies to improve the poor outcomes of current combination treatments. - Source: PubMed
Publication date: 2026/01/12
Koyama HiroakiSeo SachikoTse WilliamBian SichengLiu Shujun - Postoperative neurocognitive disorders (PND) are prevalent complications in the elderly following surgical interventions and anesthesia, with the underlying protective and damaging mechanisms remaining largely elusive. Impulsive-like behaviors and a decline in cognitive function were observed in the mouse model of PND established through tibial fracture surgery, accompanied by increased activity of astrocytes in the hippocampal CA1 region. Additionally, transcriptome sequencing revealed increased expression of nicotinic acetylcholine receptors (nAChRs) in PND. In this study, we aimed to investigate the role of nAChRs in the pathogenesis of PND in aging mice. In 18-month-old male C57BL/6 mice, a PND model was established by tibial fracture surgery, and brain tissues were collected for transcriptomic sequencing 24 h post-surgery. Behavioral assessments of PND mice were conducted using open field, light-dark box, and fear conditioning tests. An nAChRs inhibitor, Adiphenine (125 nM per day), was administered daily for 7 days via intracerebroventricular microinfusion. Pathological changes were observed using immunofluorescence staining and Western blotting, and hippocampal CA1 spikes activity and local field potentials (LFP) were monitored with a microelectrode array. Transcriptomic sequencing of the brains of PND mice revealed upregulation of Cholinergic Receptor Nicotinic Beta 2 Subunit (Chrnb2) and Cholinergic Receptor Nicotinic Beta 4 Subunit (Chrnb4). Additionally, there was an increase in neuronal spikes and enhanced LFP power in the hippocampal CA1 region, along with an increase in the number and morphological changes of astrocytes. Adiphenine was able to inhibit tibial surgery-induced impulsive-like behaviors, but it showed no significant improvement in cognitive function. It also reduced spikes firing and LFP power in the CA1 region. Our study revealed that anesthesia and surgery-induced PND models exhibit impulsive-like behaviors and cognitive impairment. Astrocyte activation and elevated Vglut1 expression may be contributing factors, with nAChRs likely playing an initiating role in this process. Adiphenine can improve impulsive-like behaviors by inhibiting nAChRs. - Source: PubMed
Peng Heng-YueGao Yi-LongWang Lu-YingLv Jin-MengMiao Hui-TaoLi Liang-YaSong Rong-XinZhou Ting-TingAn PingZhao Xiao-ChunZhang Li-Min - This study aimed to investigate the therapeutic potential of bilberry extract combined with docosahexaenoic acid (DHA) in myopia management by examining their effects on Chrnb4 gene expression in the sclera of lens-induced myopic guinea pigs and elucidating the underlying regulatory mechanisms, thereby providing a theoretical foundation for the development of natural active component-based myopia prevention and treatment strategies. - Source: PubMed
Publication date: 2025/06/04
Zhu Mei-HongWen QianLin Tai-NanGao YunLiu Xiao-TingLin Jing-HuaLin MiaoShi Qiao-Mei - Areca nut (AN) was classified as a carcinogen by the International Agency for Research on Cancer (IARC) of the WHO in 2003. AN has the same carcinogenic components as cigarettes, such as benzo[a]pyrene (B[a]P) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), but its effects on interactions with genetic factors related to lung cancer have rarely been investigated. METHODS: Here, a propensity score-matched case‒control study was conducted in Hainan, which included 445 patients with lung cancer and 445 cancer-free controls. Then, the associations between single-nucleotide polymorphisms (SNPs) in the CHRNA5-CHRNA3-CHRNB4 gene cluster and their interaction effects with AN chewing and smoking on lung cancer were analyzed. In addition, we explored the associations among AN, cigarettes, and genes related to lung cancer using the Comparative Toxicogenomics Database (CTD). - Source: PubMed
Publication date: 2025/04/07
Li YixuanZhou JingLiu LirongZhu ChaoyongLuo ZiyueLi NaLyu PengfeiZhang JingXie TianDing YipengXiao Sha